Evidence map›Paper›PMID 40115748›Full record

ArticleNAR cancer2025

Matrix stiffness modulates androgen response genes and chromatin state in prostate cancer.

Roosa Kaarijärvi, Heidi Kaljunen, Onni Niemi, Merja Räsänen, Ville Paakinaho, Kirsi Ketola

Abstract read
In one paragraph

Article in NAR cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Biology · 2025
    Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Roosa KaarijärviInstitute of Biomedicine, University of Eastern Finland, 70210, Kuopio, Finland.
Heidi KaljunenInstitute of Biomedicine, University of Eastern Finland, 70210, Kuopio, Finland.
Onni NiemiInstitute of Biomedicine, University of Eastern Finland, 70210, Kuopio, Finland.
Merja RäsänenInstitute of Biomedicine, University of Eastern Finland, 70210, Kuopio, Finland.
Ville PaakinahoInstitute of Biomedicine, University of Eastern Finland, 70210, Kuopio, Finland.ORCID 0000-0003-4204-1436
Kirsi KetolaInstitute of Biomedicine, University of Eastern Finland, 70210, Kuopio, Finland.ORCID 0000-0001-6484-9861

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The interplay between the extracellular matrix (ECM) and prostate cancer has been shown to increase ECM stiffness, correlating with more aggressive disease forms. However, the impact of ECM stiffness on the androgen receptor (AR), a key target in prostate cancer treatment, remains elusive. Here, we investigated whether matrix stiffness influences prostate cancer progression, transcriptional regulation, chromatin state, and AR function in AR-positive prostate cancer cells under varying ECM stiffness conditions. We utilized ATAC-seq (assay for transposase-accessible chromatin with sequencing) and RNA sequencing under different ECM conditions, along with the SUC2 metastatic prostate adenocarcinoma patient dataset, to investigate the role of ECM stiffness in chromatin state and androgen response genes, as well as its impact on prostate cancer progression. Results demonstrated that increased ECM stiffness elevated the expression of genes related to proliferation and differentiation. In contrast, androgen response genes were most highly induced in soft ECM conditions. Integrating chromatin accessibility with transcriptomic data revealed that androgen response genes were more transcriptionally available in soft ECM conditions. Additionally, increased ECM stiffness upregulated genes associated with low overall survival in the SUC2 dataset. Taken together, our results indicate that high expression of hard matrix stiffness genes may promote prostate cancer progression, leading to more aggressive disease forms associated with poor survival.

Indexed as

AndrogensChromatinExtracellular MatrixProstatic NeoplasmsReceptors, AndrogenCell Line, TumorDisease ProgressionGene Expression Regulation, NeoplasticHumansMaleAndrogensAR protein, humanChromatinReceptors, Androgen

Identifiers

PMID40115748
PMCPMC11923743

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.